StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Constant Currency Growth in Rest of World (% cc) by Year

Constant Currency Growth in Rest of World (% cc) (%)

Novartis Constant Currency Growth in Rest of World (% cc): 2.0% in FY2025, unchanged from a year earlier.

Latest, FY2025
2.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
2.0% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Sandostatin Group | Established brands | Carcinoid tumors, acromegaly | 729 | -9 | 484 | 2 | 2 | 1 213 | -5 | -5”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConstant Currency Growth in Rest of World (% cc) (%)Year on yearSource
FY2025Dec 31, 20252.0%0.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 20242.0%-13.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
FY2023Dec 31, 202315.0%+31.0 ptsNovartis Form 6-K (0001370368-24-000007) ↗
FY2022Dec 31, 2022-16.0%-8.0 ptsNovartis Form 6-K (0001370368-23-000008) ↗
FY2021Dec 31, 2021-8.0%+5.0 ptsNovartis Form 6-K (0001370368-22-000009) ↗
FY2020Dec 31, 2020-13.0%-10.0 ptsNovartis Form 6-K (0001370368-21-000008) ↗
FY2019Dec 31, 2019-3.0%-2.0 ptsNovartis Form 6-K (0001370368-20-000007) ↗
FY2018Dec 31, 2018-1.0%–Novartis Form 6-K (0001370368-19-000006) ↗

Cite this data

StockData. (2026). Novartis Constant Currency Growth in Rest of World (% cc) (%), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-sandostatin-group-row-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.